THE Therapeutic Goods Administration is inviting comments on a proposal to reschedule Sativex (nabiximols) from its current S8 classification to Schedule 4.
The product is a botanical extract of cannabis sativa in a buccal spray, with the application noting that it is currently available on prescription in 26 countries with scheduling that is similar to S4 in Australia.
The Advisory Committee for Medicines Scheduling is also considering a proposal to create a new Schedule 4 group entry for racetams, with input on the consultation sought by 28 Sep - for details see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Sep 18
